Global Myelodysplastic Syndrome

Myelodysplastic Syndrome Comprehensive Study by Type (Alkylating Agents, Cytotoxic Antibiotics, Topoisomerase Inhibitors, Others), Application (Hospital, Clinic), Route of Administration (Generic, Oral), Therapeutic (Immunomodulatory Drugs, Hypomethylating Agents, Chemotherapy, Blood Transfusion, Anti-anemics, Others) Players and Region - Global Market Outlook to 2026

Myelodysplastic Syndrome Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 12.5%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Myelodysplastic syndrome (MDS) is a type of cancer which is caused due to the protection of abnormal blood cell in bone marrow. Bone marrow failure leads to a drop in the number of healthy blood cells in the body. MDS is caused by mutation of one or more genes that control the development of blood cells. Rising awareness about the disease and its symptoms with advanced methods and techniques for diagnosis and treatment for various forms of the disease is propelling the market for Myelodysplastic syndrome.
According to AMA, the market for Myelodysplastic Syndrome is expected to register a CAGR of 12.5% during the forecast period to 2026. This growth is primarily driven by Increase in Geriatric Population, Growing Number of Cancer Patients with Various Types of Cancer and Increasing Healthcare Spending Across the Globe.

Globally, a noticeable market trend is evident Blood Marrow Disorder Diagnosis and Treatment Medical procedure is Highly used for Myelodysplastic Syndrome. The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Novartis International AG (Switzerland), Bellicum Pharmaceuticals, Inc. (United States), Amgen Inc. (United States), Actinium Pharmaceuticals (United States), Eli-lilly (United States), GlaxoSmithKline (United Kingdom), Takeda Pharmaceutical Company Limited (Japan), Celator Pharmaceuticals (United States), Celgene (United States), Acceleron Pharma (United States), BioLineRx (Isreal) and Rafael Pharmaceuticals (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

On 30th July 2020, Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its investigational drug pevonedistat for the treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS).

Regulatory Insights:
"On 7th July 2020, the U.S. Food and Drug Administration approved Inqovi (decitabine and cedazuridine) tablets for the treatment of adult patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). This represents an important advance in treatment options for patients with MDS, a type of blood cancer, who previously needed to visit a health care facility to receive intravenous therapy. "

Market Drivers
  • Increase in Geriatric Population
  • Growing Number of Cancer Patients with Various Types of Cancer
  • Increasing Healthcare Spending Across the Globe

Market Trend
  • Blood Marrow Disorder Diagnosis and Treatment Medical procedure is Highly used for Myelodysplastic Syndrome

Restraints
  • Lack of Awareness about the Severity of Myelodysplastic Symptoms
  • High Treatment Cost Might Be the Reason for Negligence to Myelodysplastic Syndromes

Opportunities
Research and Development for Myelodysplastic Syndrome (MDS) Treatment and Government Support and Initiatives for Diagnosis and Treatment for Cancer
Challenges
Lack of Reach of Myelodysplastic Syndrome Treatment and Care in Rural Region of the World

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Myelodysplastic Syndrome Study Sheds Light on
— The Myelodysplastic Syndrome Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Myelodysplastic Syndrome industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Myelodysplastic Syndrome industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Alkylating Agents
  • Cytotoxic Antibiotics
  • Topoisomerase Inhibitors
  • Others
By Application
  • Hospital
  • Clinic
By Route of Administration
  • Generic
  • Oral

By Therapeutic
  • Immunomodulatory Drugs
  • Hypomethylating Agents
  • Chemotherapy
  • Blood Transfusion
  • Anti-anemics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Geriatric Population
      • 3.2.2. Growing Number of Cancer Patients with Various Types of Cancer
      • 3.2.3. Increasing Healthcare Spending Across the Globe
    • 3.3. Market Challenges
      • 3.3.1. Lack of Reach of Myelodysplastic Syndrome Treatment and Care in Rural Region of the World
    • 3.4. Market Trends
      • 3.4.1. Blood Marrow Disorder Diagnosis and Treatment Medical procedure is Highly used for Myelodysplastic Syndrome
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Myelodysplastic Syndrome, by Type, Application, Route of Administration, Therapeutic and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Myelodysplastic Syndrome (Value)
      • 5.2.1. Global Myelodysplastic Syndrome by: Type (Value)
        • 5.2.1.1. Alkylating Agents
        • 5.2.1.2. Cytotoxic Antibiotics
        • 5.2.1.3. Topoisomerase Inhibitors
        • 5.2.1.4. Others
      • 5.2.2. Global Myelodysplastic Syndrome by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinic
      • 5.2.3. Global Myelodysplastic Syndrome by: Route of Administration (Value)
        • 5.2.3.1. Generic
        • 5.2.3.2. Oral
      • 5.2.4. Global Myelodysplastic Syndrome by: Therapeutic (Value)
        • 5.2.4.1. Immunomodulatory Drugs
        • 5.2.4.2. Hypomethylating Agents
        • 5.2.4.3. Chemotherapy
        • 5.2.4.4. Blood Transfusion
        • 5.2.4.5. Anti-anemics
        • 5.2.4.6. Others
      • 5.2.5. Global Myelodysplastic Syndrome Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Myelodysplastic Syndrome (Price)
      • 5.3.1. Global Myelodysplastic Syndrome by: Type (Price)
  • 6. Myelodysplastic Syndrome: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis International AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bellicum Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Actinium Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli-lilly (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Celator Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Celgene (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Acceleron Pharma (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. BioLineRx (Isreal)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Rafael Pharmaceuticals (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Myelodysplastic Syndrome Sale, by Type, Application, Route of Administration, Therapeutic and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Myelodysplastic Syndrome (Value)
      • 7.2.1. Global Myelodysplastic Syndrome by: Type (Value)
        • 7.2.1.1. Alkylating Agents
        • 7.2.1.2. Cytotoxic Antibiotics
        • 7.2.1.3. Topoisomerase Inhibitors
        • 7.2.1.4. Others
      • 7.2.2. Global Myelodysplastic Syndrome by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinic
      • 7.2.3. Global Myelodysplastic Syndrome by: Route of Administration (Value)
        • 7.2.3.1. Generic
        • 7.2.3.2. Oral
      • 7.2.4. Global Myelodysplastic Syndrome by: Therapeutic (Value)
        • 7.2.4.1. Immunomodulatory Drugs
        • 7.2.4.2. Hypomethylating Agents
        • 7.2.4.3. Chemotherapy
        • 7.2.4.4. Blood Transfusion
        • 7.2.4.5. Anti-anemics
        • 7.2.4.6. Others
      • 7.2.5. Global Myelodysplastic Syndrome Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Myelodysplastic Syndrome (Price)
      • 7.3.1. Global Myelodysplastic Syndrome by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Myelodysplastic Syndrome: by Type(USD Million)
  • Table 2. Myelodysplastic Syndrome Alkylating Agents , by Region USD Million (2015-2020)
  • Table 3. Myelodysplastic Syndrome Cytotoxic Antibiotics , by Region USD Million (2015-2020)
  • Table 4. Myelodysplastic Syndrome Topoisomerase Inhibitors , by Region USD Million (2015-2020)
  • Table 5. Myelodysplastic Syndrome Others , by Region USD Million (2015-2020)
  • Table 6. Myelodysplastic Syndrome: by Application(USD Million)
  • Table 7. Myelodysplastic Syndrome Hospital , by Region USD Million (2015-2020)
  • Table 8. Myelodysplastic Syndrome Clinic , by Region USD Million (2015-2020)
  • Table 9. Myelodysplastic Syndrome: by Route of Administration(USD Million)
  • Table 10. Myelodysplastic Syndrome Generic , by Region USD Million (2015-2020)
  • Table 11. Myelodysplastic Syndrome Oral , by Region USD Million (2015-2020)
  • Table 12. Myelodysplastic Syndrome: by Therapeutic(USD Million)
  • Table 13. Myelodysplastic Syndrome Immunomodulatory Drugs , by Region USD Million (2015-2020)
  • Table 14. Myelodysplastic Syndrome Hypomethylating Agents , by Region USD Million (2015-2020)
  • Table 15. Myelodysplastic Syndrome Chemotherapy , by Region USD Million (2015-2020)
  • Table 16. Myelodysplastic Syndrome Blood Transfusion , by Region USD Million (2015-2020)
  • Table 17. Myelodysplastic Syndrome Anti-anemics , by Region USD Million (2015-2020)
  • Table 18. Myelodysplastic Syndrome Others , by Region USD Million (2015-2020)
  • Table 19. South America Myelodysplastic Syndrome, by Country USD Million (2015-2020)
  • Table 20. South America Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 21. South America Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 22. South America Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 23. South America Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 24. Brazil Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 25. Brazil Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 26. Brazil Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 27. Brazil Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 28. Argentina Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 29. Argentina Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 30. Argentina Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 31. Argentina Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 32. Rest of South America Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 33. Rest of South America Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 34. Rest of South America Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 35. Rest of South America Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 36. Asia Pacific Myelodysplastic Syndrome, by Country USD Million (2015-2020)
  • Table 37. Asia Pacific Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 38. Asia Pacific Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 39. Asia Pacific Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 40. Asia Pacific Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 41. China Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 42. China Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 43. China Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 44. China Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 45. Japan Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 46. Japan Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 47. Japan Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 48. Japan Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 49. India Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 50. India Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 51. India Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 52. India Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 53. South Korea Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 54. South Korea Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 55. South Korea Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 56. South Korea Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 57. Taiwan Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 58. Taiwan Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 59. Taiwan Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 60. Taiwan Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 61. Australia Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 62. Australia Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 63. Australia Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 64. Australia Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 69. Europe Myelodysplastic Syndrome, by Country USD Million (2015-2020)
  • Table 70. Europe Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 71. Europe Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 72. Europe Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 73. Europe Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 74. Germany Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 75. Germany Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 76. Germany Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 77. Germany Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 78. France Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 79. France Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 80. France Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 81. France Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 82. Italy Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 83. Italy Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 84. Italy Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 85. Italy Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 86. United Kingdom Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 87. United Kingdom Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 88. United Kingdom Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 89. United Kingdom Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 90. Netherlands Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 91. Netherlands Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 92. Netherlands Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 93. Netherlands Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 94. Rest of Europe Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 95. Rest of Europe Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 96. Rest of Europe Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 97. Rest of Europe Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 98. MEA Myelodysplastic Syndrome, by Country USD Million (2015-2020)
  • Table 99. MEA Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 100. MEA Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 101. MEA Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 102. MEA Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 103. Middle East Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 104. Middle East Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 105. Middle East Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 106. Middle East Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 107. Africa Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 108. Africa Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 109. Africa Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 110. Africa Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 111. North America Myelodysplastic Syndrome, by Country USD Million (2015-2020)
  • Table 112. North America Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 113. North America Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 114. North America Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 115. North America Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 116. United States Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 117. United States Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 118. United States Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 119. United States Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 120. Canada Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 121. Canada Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 122. Canada Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 123. Canada Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 124. Mexico Myelodysplastic Syndrome, by Type USD Million (2015-2020)
  • Table 125. Mexico Myelodysplastic Syndrome, by Application USD Million (2015-2020)
  • Table 126. Mexico Myelodysplastic Syndrome, by Route of Administration USD Million (2015-2020)
  • Table 127. Mexico Myelodysplastic Syndrome, by Therapeutic USD Million (2015-2020)
  • Table 128. Myelodysplastic Syndrome: by Type(USD/Units)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Myelodysplastic Syndrome: by Type(USD Million)
  • Table 142. Myelodysplastic Syndrome Alkylating Agents , by Region USD Million (2021-2026)
  • Table 143. Myelodysplastic Syndrome Cytotoxic Antibiotics , by Region USD Million (2021-2026)
  • Table 144. Myelodysplastic Syndrome Topoisomerase Inhibitors , by Region USD Million (2021-2026)
  • Table 145. Myelodysplastic Syndrome Others , by Region USD Million (2021-2026)
  • Table 146. Myelodysplastic Syndrome: by Application(USD Million)
  • Table 147. Myelodysplastic Syndrome Hospital , by Region USD Million (2021-2026)
  • Table 148. Myelodysplastic Syndrome Clinic , by Region USD Million (2021-2026)
  • Table 149. Myelodysplastic Syndrome: by Route of Administration(USD Million)
  • Table 150. Myelodysplastic Syndrome Generic , by Region USD Million (2021-2026)
  • Table 151. Myelodysplastic Syndrome Oral , by Region USD Million (2021-2026)
  • Table 152. Myelodysplastic Syndrome: by Therapeutic(USD Million)
  • Table 153. Myelodysplastic Syndrome Immunomodulatory Drugs , by Region USD Million (2021-2026)
  • Table 154. Myelodysplastic Syndrome Hypomethylating Agents , by Region USD Million (2021-2026)
  • Table 155. Myelodysplastic Syndrome Chemotherapy , by Region USD Million (2021-2026)
  • Table 156. Myelodysplastic Syndrome Blood Transfusion , by Region USD Million (2021-2026)
  • Table 157. Myelodysplastic Syndrome Anti-anemics , by Region USD Million (2021-2026)
  • Table 158. Myelodysplastic Syndrome Others , by Region USD Million (2021-2026)
  • Table 159. South America Myelodysplastic Syndrome, by Country USD Million (2021-2026)
  • Table 160. South America Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 161. South America Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 162. South America Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 163. South America Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 164. Brazil Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 165. Brazil Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 166. Brazil Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 167. Brazil Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 168. Argentina Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 169. Argentina Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 170. Argentina Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 171. Argentina Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 172. Rest of South America Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 173. Rest of South America Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 174. Rest of South America Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 175. Rest of South America Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 176. Asia Pacific Myelodysplastic Syndrome, by Country USD Million (2021-2026)
  • Table 177. Asia Pacific Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 178. Asia Pacific Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 179. Asia Pacific Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 180. Asia Pacific Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 181. China Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 182. China Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 183. China Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 184. China Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 185. Japan Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 186. Japan Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 187. Japan Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 188. Japan Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 189. India Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 190. India Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 191. India Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 192. India Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 193. South Korea Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 194. South Korea Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 195. South Korea Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 196. South Korea Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 197. Taiwan Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 198. Taiwan Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 199. Taiwan Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 200. Taiwan Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 201. Australia Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 202. Australia Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 203. Australia Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 204. Australia Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 209. Europe Myelodysplastic Syndrome, by Country USD Million (2021-2026)
  • Table 210. Europe Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 211. Europe Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 212. Europe Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 213. Europe Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 214. Germany Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 215. Germany Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 216. Germany Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 217. Germany Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 218. France Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 219. France Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 220. France Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 221. France Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 222. Italy Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 223. Italy Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 224. Italy Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 225. Italy Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 226. United Kingdom Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 227. United Kingdom Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 228. United Kingdom Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 229. United Kingdom Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 230. Netherlands Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 231. Netherlands Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 232. Netherlands Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 233. Netherlands Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 234. Rest of Europe Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 235. Rest of Europe Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 236. Rest of Europe Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 237. Rest of Europe Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 238. MEA Myelodysplastic Syndrome, by Country USD Million (2021-2026)
  • Table 239. MEA Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 240. MEA Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 241. MEA Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 242. MEA Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 243. Middle East Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 244. Middle East Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 245. Middle East Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 246. Middle East Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 247. Africa Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 248. Africa Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 249. Africa Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 250. Africa Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 251. North America Myelodysplastic Syndrome, by Country USD Million (2021-2026)
  • Table 252. North America Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 253. North America Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 254. North America Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 255. North America Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 256. United States Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 257. United States Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 258. United States Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 259. United States Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 260. Canada Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 261. Canada Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 262. Canada Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 263. Canada Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 264. Mexico Myelodysplastic Syndrome, by Type USD Million (2021-2026)
  • Table 265. Mexico Myelodysplastic Syndrome, by Application USD Million (2021-2026)
  • Table 266. Mexico Myelodysplastic Syndrome, by Route of Administration USD Million (2021-2026)
  • Table 267. Mexico Myelodysplastic Syndrome, by Therapeutic USD Million (2021-2026)
  • Table 268. Myelodysplastic Syndrome: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Myelodysplastic Syndrome: by Type USD Million (2015-2020)
  • Figure 5. Global Myelodysplastic Syndrome: by Application USD Million (2015-2020)
  • Figure 6. Global Myelodysplastic Syndrome: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Myelodysplastic Syndrome: by Therapeutic USD Million (2015-2020)
  • Figure 8. South America Myelodysplastic Syndrome Share (%), by Country
  • Figure 9. Asia Pacific Myelodysplastic Syndrome Share (%), by Country
  • Figure 10. Europe Myelodysplastic Syndrome Share (%), by Country
  • Figure 11. MEA Myelodysplastic Syndrome Share (%), by Country
  • Figure 12. North America Myelodysplastic Syndrome Share (%), by Country
  • Figure 13. Global Myelodysplastic Syndrome: by Type USD/Units (2015-2020)
  • Figure 14. Global Myelodysplastic Syndrome share by Players 2020 (%)
  • Figure 15. Global Myelodysplastic Syndrome share by Players (Top 3) 2020(%)
  • Figure 16. Global Myelodysplastic Syndrome share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. Bellicum Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bellicum Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 24. Actinium Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 25. Actinium Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 26. Eli-lilly (United States) Revenue, Net Income and Gross profit
  • Figure 27. Eli-lilly (United States) Revenue: by Geography 2020
  • Figure 28. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 30. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2020
  • Figure 32. Celator Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 33. Celator Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 34. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 35. Celgene (United States) Revenue: by Geography 2020
  • Figure 36. Acceleron Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 37. Acceleron Pharma (United States) Revenue: by Geography 2020
  • Figure 38. BioLineRx (Isreal) Revenue, Net Income and Gross profit
  • Figure 39. BioLineRx (Isreal) Revenue: by Geography 2020
  • Figure 40. Rafael Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 41. Rafael Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 42. Global Myelodysplastic Syndrome: by Type USD Million (2021-2026)
  • Figure 43. Global Myelodysplastic Syndrome: by Application USD Million (2021-2026)
  • Figure 44. Global Myelodysplastic Syndrome: by Route of Administration USD Million (2021-2026)
  • Figure 45. Global Myelodysplastic Syndrome: by Therapeutic USD Million (2021-2026)
  • Figure 46. South America Myelodysplastic Syndrome Share (%), by Country
  • Figure 47. Asia Pacific Myelodysplastic Syndrome Share (%), by Country
  • Figure 48. Europe Myelodysplastic Syndrome Share (%), by Country
  • Figure 49. MEA Myelodysplastic Syndrome Share (%), by Country
  • Figure 50. North America Myelodysplastic Syndrome Share (%), by Country
  • Figure 51. Global Myelodysplastic Syndrome: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Novartis International AG (Switzerland)
  • Bellicum Pharmaceuticals, Inc. (United States)
  • Amgen Inc. (United States)
  • Actinium Pharmaceuticals (United States)
  • Eli-lilly (United States)
  • GlaxoSmithKline (United Kingdom)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Celator Pharmaceuticals (United States)
  • Celgene (United States)
  • Acceleron Pharma (United States)
  • BioLineRx (Isreal)
  • Rafael Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Otsuka Pharmaceutical Co., Ltd. (Japan) , Sandoz Inc. (Germany)
Select User Access Type

Key Highlights of Report


Sep 2021 232 Pages 93 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Myelodysplastic Syndrome Quantitative research analysis
Global Myelodysplastic Syndrome Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Myelodysplastic Syndrome market is expected to see a CAGR of 12.5% during projected year 2020 to 2026.
Top performing companies in the Global Myelodysplastic Syndrome market are Novartis International AG (Switzerland), Bellicum Pharmaceuticals, Inc. (United States), Amgen Inc. (United States), Actinium Pharmaceuticals (United States), Eli-lilly (United States), GlaxoSmithKline (United Kingdom), Takeda Pharmaceutical Company Limited (Japan), Celator Pharmaceuticals (United States), Celgene (United States), Acceleron Pharma (United States), BioLineRx (Isreal) and Rafael Pharmaceuticals (United States), to name a few.
North America is dominating the Myelodysplastic Syndrome Market.

Know More About Global Myelodysplastic Syndrome Report?

Have a Query? Click Here

Other Related Reports

Vertebral Compression Fracture Devices Comprehensive Study by Type (Balloon Kyphoplasty Devices, Vertebroplasty Devices), Surgery Type (Open Spine Surgery, Minimally Invasive Spine Surgery, Lumbar Fu...
$ 3650
Chronic Obstructive Pulmonary Disease Comprehensive Study by Disease Type (Emphysema, Chronic Bronchitis), Age Group (Children, Adults), Treatment Type (Medication, Oxygen Therapy, Pulmonary Rehabili...
$ 3800
T-Cell Immunotherapy Comprehensive Study by Type (Active Immunotherapy, Passive Immunotherapy), Application (Stomach Cancer, Lung Cancer, Colorectal Cancer, Esophagus Cancer, Pancreatic Cancer, Other...
$ 3750
Malaria Diagnostics Comprehensive Study by Type (Microscopy, Rapid Diagnostic Tests, Molecular Diagnostic Tests (Conventional PCR, Real-Time PCR (quantitative PCR or qPCR))), End User (Clinics, Hospi...
$ 3350
Minimally Invasive Surgery Comprehensive Study by Type (Endoscopic Devices, Electrosurgical Devices, Monitoring and Visualization Devices), Application (Cosmetic Surgery, Cardiac Surgery, Gastrointes...
$ 3650
Therapeutic Drug Monitoring Comprehensive Study by Type (Consumable, Equipment (Immunoassay analyzer)), Application (Hospitals (Clinical Pharmacology departments), Pathological labs, Research and Aca...
$ 3750